Predictive biomarkers of ICI response in ES-SCLC. SCLC: small cell lung cancer; ES: extensive stage; PD-L1: programmed cell death 1 ligand 1; ICI: immune checkpoint inhibitor; TMB: tumor mutational burden; tTMB: tissue tumor mutational burden; bTMB: blood tumor mutational burden; TME: tumor ...
Long term survivorsRecently, the emergence of immune checkpoint inhibitors has significantly improved the survival of patients with extensive-stage small cell lung cancer. However, not all patients can benefit from immunotherapy; therefore, there is an urgent need for precise predictive markers to ...
Twenty-five untreated patients with extensive stage small cell lung cancer (ESSCLC) were treated with carboplatin (CBDCA) (500 mg/m2) given as a 24-hour infusion every 21 days. Thirteen patients responded for an overall response rate of 52% (95% confidence limits, 32% to 72%) with 3 ...
Three long‐term survivors were seen in the latter group.doi:10.1002/1097-0142(19910515)67:10<2443::aid-cncr2820671008>3.0.coKaasa S. et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer. 1991; 67 (10):2443–2447....